Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim H Ward

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|August 17, 2010
Fit-for-purpose biomarker method validation in anticancer drug developmentJeffrey Cummings, Tim H Ward, Caroline Dive
Biochimica Et Biophysica Acta|December 9, 2004
Apoptosis pathway-targeted drugs--from the bench to the clinicJeff Cummings, Tim H Ward, Malcolm Ranson, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Circulating tumour cells: their utility in cancer management and predicting outcomesMatthew G Krebs, Jian-Mei Hou, Tim H Ward, et al.
The Journal of Pathology. Clinical Research|October 18, 2021
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirationsTim H Ward, Duncan C Gilbert, George Higginbotham, et al.
Molecular Cancer Therapeutics|March 19, 2008
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activityJeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancerMatthew G Krebs, Robert Sloane, Lynsey Priest, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2011
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approachesMatthew G Krebs, Jian-Mei Hou, Robert Sloane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effectsAdam J Webb, Emily Harper, Tim Rattay, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|August 17, 2010
Fit-for-purpose biomarker method validation in anticancer drug developmentJeffrey Cummings, Tim H Ward, Caroline Dive
Biochimica Et Biophysica Acta|December 9, 2004
Apoptosis pathway-targeted drugs--from the bench to the clinicJeff Cummings, Tim H Ward, Malcolm Ranson, et al.
Therapeutic Advances in Medical Oncology|July 27, 2011
Circulating tumour cells: their utility in cancer management and predicting outcomesMatthew G Krebs, Jian-Mei Hou, Tim H Ward, et al.
The Journal of Pathology. Clinical Research|October 18, 2021
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirationsTim H Ward, Duncan C Gilbert, George Higginbotham, et al.
Molecular Cancer Therapeutics|March 19, 2008
Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activityJeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancerMatthew G Krebs, Robert Sloane, Lynsey Priest, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2011
Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approachesMatthew G Krebs, Jian-Mei Hou, Robert Sloane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Circadian genotypes in PER3 and time of prostate cancer radiotherapy interact to affect risk of late side-effectsAdam J Webb, Emily Harper, Tim Rattay, et al.
Pageof 1